Advertisement Cancer Research UK aims to increase funding into cancer research - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Cancer Research UK aims to increase funding into cancer research

Cancer Research UK aims to increase funding into research by over 50% during the next five to ten years as part of its ambitious new research strategy, launching on 29 April 2014.

This rise in funding will support ongoing research into preventing cancer, developing new treatments and making existing ones more effective and personalised to the patient. The charity will substantially increase investment in research aimed at earlier detection and diagnosis.

Over the coming years Cancer Research UK will invest an additional £50m a year into a number of new funding streams designed to encourage partnership and collaboration between researchers as well as harness the UK’s strength in engineering and physical sciences to address challenges in cancer.

New areas include: A ‘grand challenge’ award scheme designed to bring together groups of researchers in academia and industry, both here and overseas to answer the biggest questions in cancer. These awards will be worth up to £20m; An innovation award open to all areas of cancer research for high-risk but high-reward research that takes innovative approaches to tackle unanswered questions in cancer; New career development awards to support clinical and non-clinical mid-career researchers at a critical time in their working life to develop their own independent research groups – this will complement Cancer Research UK’s existing £13m investment in fellowship schemes.

The new areas also include: A multidisciplinary award to enable collaborations that use approaches in physics, engineering, chemistry or mathematics in the hunt for new ways to prevent, diagnose or treat cancer; Immunology grants – a new scheme to harness the strength in UK immunology research and bring more researchers to the growing field of cancer immunology, building on recent successes in immunotherapies; and Additional funding to the national network of Cancer Research UK Centres to build a world-class infrastructure for translational research.

In addition, Cancer Research UK will continue to fund and increase investment to all existing funding streams, and where appropriate these schemes will be opened up to international researchers.

Cancer Research UK chief scientist Dr Nic Jones noted that their understanding of cancer has been transformed over the last few years and its new strategy looks to place Cancer Research UK at the heart of future advances and ensure that UK cancer research continues to punch well above its weight on the international stage.

"We want to bring new researchers into cancer research – from a range of different disciplines and give them the freedom and flexibility to pursue their boldest ideas. Our strategy will support the best scientists and doctors throughout their careers – from those making their first steps to world-leading researchers – to make this a reality.

"We want to excite the research community to tackle the biggest questions in cancer so we can accelerate our understanding in order to bring real benefits for patients – from detecting the disease earlier to better and kinder treatments," Dr Jones added.

An increase of over £20m a year will be invested into research to improve the earlier diagnosis of cancer which has the potential to save many more lives. This will span fundamental research to understand better the very early stages of cancer, to the development of tests to detect different forms of the disease earlier.

And the research strategy plans to at least double funding into four types of cancer with substantial unmet need – lung, pancreatic, oesophageal and brain – where there has been limited progress in improving survival rates. Recent investments in Cancer Research UK’s Stratified Medicine Programme and the Tracer X lung cancer study are examples of the approach the charity will take.